OncoMatch/Clinical Trials/NCT07353671
Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis
Is NCT07353671 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies Topical application of Periplaneta americana-derived Meilian Fuxin Solution for radiation-induced dermatitis.
Treatment: Topical application of Periplaneta americana-derived Meilian Fuxin Solution — To evaluate the efficacy and safety of topical Periplaneta americana-derived Meilian Fuxin Solution for the prevention of radiation dermatitis in patients undergoing radiotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07353671 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify